Healthcare Industry News: cardiac imaging
News Release - October 16, 2007
Positron Displays PULSE CDC(TM) and Introduces New Cardiac PET Scanner at the Annual Meeting of the American Society of Nuclear CardiologyHOUSTON--(HSMN NewsFeed)--Positron Corporation (OTCBB:POSC ) displayed their PULSE CDC(TM) SPECT imaging system as well as introduced their new dedicated Cardiac PET system that is expected to receive 510k FDA approval in spring 2008 at the annual meeting of the American Society of Nuclear Cardiology. The meeting attendees consisted of more than 1,500 nuclear cardiologists, practice administrators and technologists with the majority operating myocardial perfusion imaging with private cardiology practices.
Market research from the ASNC meeting suggested that the cardiologist market would readily move to compliment their molecular imaging offering by adding Positron's cost effective Attrius system, especially due to the proposed cardiac PET reimbursement increase (Jan 1, 2008).
Positron is expecting significant demand for their product since they will be the only vendor offering an all new PET only molecular imaging system for less than $600,000 with the primary focus on cardiology. Positron intends to be the first company to offer absolute coronary flow reserve calculations developed by K. Lance Gould, M.D. Dr. Gould is considered the founder of Cardiac PET combined with the discovery of flow reserve in human studies.
Positron Corporation's President, Joseph Oliverio stated, "The American Society of Nuclear Cardiology meeting confirmed our internal market research. We strongly believe that we are in a great position to be the leader in the rapidly expanding market of Cardiac PET. We will be the only company that is focused on bringing to market an affordable dedicated cardiac PET scanner with superior technology and disease focused software. We anticipate receiving our 510k FDA approval in spring of 2008."
Positron Corporation designs, manufactures, markets and supports advanced cardiac molecular imaging devices utilizing single photon emission computed tomography (SPECT) and positron emission tomography (PET). The company's molecular imaging systems incorporate patented and proprietary software and hardware technology for the diagnosis and treatment of patients with heart disease. Positron Corporation offers unique combination of low cost technology and disease specific software solutions differentiating themselves from all other medical device manufacturers. Additional information may be found at http://www.positron.com and http://www.is2medical.com.
Forward Looking Statements:
Statements in this document contain certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended. These statements are based on many assumptions and estimates and are not guarantees of future performance and may involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Positron Corporation to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements. The words "expect," "anticipate," "intend," "plan," "believe," "seek," "estimate," and similar expressions are intended to identify such forward-looking statements. Our actual results may differ materially from the results anticipated in these forward-looking statements due to a variety of factors, including, without limitation those set forth as "Risk Factors" in our filings with the Securities and Exchange Commission.
For further information please contact Positron Corporation at (281) 492-7100.
Source: Positron Corporation
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.